NASDAQ:SCNI Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis $1.32 +0.01 (+0.76%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Scinai Immunotherapeutics Stock (NASDAQ:SCNI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SCNI alerts:Sign Up Key Stats Today's Range$1.30▼$1.3050-Day Range$1.31▼$3.2252-Week Range$1.27▼$16.30Volume9,321 shsAverage Volume490,393 shsMarket Capitalization$937.20 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company is developing treatments designed to target disease-related immune pathways while potentially providing localized delivery and reduced systemic exposure. Scinai’s development platform is based on NanoAbs, or nanobodies, which are small antibody-derived molecules intended to bind selectively to therapeutic targets. Its lead program is an anti-IL-17 NanoAb candidate being developed for topical treatment of psoriasis and potentially other inflammatory conditions. The company is also evaluating additional applications for its platform across immune-mediated diseases. Scinai serves the biopharmaceutical market through research and development of its proprietary therapeutic candidates and technology platform. The company is headquartered in Israel and is conducting its work as a development-stage biotechnology business; product candidates remain subject to clinical testing and regulatory review before they can be marketed.AI Generated. May Contain Errors. Read More Scinai Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreSCNI MarketRank™: Scinai Immunotherapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingScinai Immunotherapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageScinai Immunotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Scinai Immunotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScinai Immunotherapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Scinai Immunotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted163.64% of the float of Scinai Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverScinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scinai Immunotherapeutics has recently increased by 5,382.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScinai Immunotherapeutics does not currently pay a dividend.Dividend GrowthScinai Immunotherapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentScinai Immunotherapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Scinai Immunotherapeutics this week, compared to 1 article on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders60.90% of the stock of Scinai Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scinai Immunotherapeutics' insider trading history. Receive SCNI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCNI Stock News HeadlinesScinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest UpdateSeptember 26, 2026 | americanbankingnews.comSCINAI IMMUNOTHERAPEUTICS LTD: Scinai Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 21, 2026 | finanznachrichten.deThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 2 at 1:00 AM | Investors Alley (Ad)Scinai Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 21, 2026 | prnewswire.comScinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO BusinessSeptember 8, 2026 | prnewswire.comScinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call TranscriptAugust 26, 2026 | seekingalpha.comScinai Immunotherapeutics Ltd (SCNI) Stock Price, Quote, News & HistoryAugust 25, 2026 | benzinga.comScinai Immunotherapeutics Ltd.: Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO MomentumAugust 24, 2026 | finanznachrichten.deSee More Headlines SCNI Stock Analysis - Frequently Asked Questions How have SCNI shares performed this year? Scinai Immunotherapeutics' stock was trading at $7.1210 at the beginning of the year. Since then, SCNI stock has decreased by 81.6% and is now trading at $1.31. How were Scinai Immunotherapeutics' earnings last quarter? Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) issued its earnings results on Wednesday, May, 7th. The company reported ($104.00) earnings per share (EPS) for the quarter. The company earned $0.21 million during the quarter. When did Scinai Immunotherapeutics' stock split? Shares of Scinai Immunotherapeutics reverse split on Tuesday, May 21st 2024.The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Scinai Immunotherapeutics IPO? Scinai Immunotherapeutics (SCNI) raised $14 million in an initial public offering on Friday, May 1st 2015. The company issued 1,910,000 shares at a price of $7.32 per share. How do I buy shares of Scinai Immunotherapeutics? Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scinai Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON). Company Calendar Last Earnings5/07/2025Today10/02/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SCNI's financial health is in the Red zone, according to TradeSmith. SCNI has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SCNI Previous SymbolNASDAQ:SCNI CIK1611747 Webwww.scinai.com Phone972-8-930-2529Fax972-8930-2531Employees45Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio1.56 Quick Ratio1.35 Sales & Book Value Annual Sales$1.31 million Price / Sales0.72 Cash FlowN/A Price / Cash FlowN/A Book Value$7.77 per share Price / Book0.17Miscellaneous Outstanding Shares710,000Free Float276,000Market Cap$937.20 thousand OptionableNot Optionable Beta2.13 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SCNI) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredThe last few crashes started exactly like thisEvery major market crash shared one thing in common: most investors felt confident right before it hit. Ove...Parkview Capital Group | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
